A Prospective Cohort of Children With HIV Infection
This study is currently recruiting participants.
Verified April 2012 by The HIV Netherlands Australia Thailand Research Collaboration
Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborator:
Khon Kaen University
Information provided by (Responsible Party):
The HIV Netherlands Australia Thailand Research Collaboration
ClinicalTrials.gov Identifier:
NCT00476606
First received: May 20, 2007
Last updated: April 3, 2012
Last verified: April 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To evaluate clinical and immunological outcome of children treated with HAART.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections |
Drug: Zidovudine, Stavudine, Didanosine, Lamivudine Drug: Nevirapine, Efavirenz Drug: LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Treatment Outcome of Children With HIV Infection |
Resource links provided by NLM:
Genetics Home Reference related topics:
complement factor I deficiency
MedlinePlus related topics:
HIV/AIDS
Drug Information available for:
Stavudine
Zidovudine
Didanosine
Saquinavir
Nevirapine
Lamivudine
Saquinavir mesylate
Indinavir
Efavirenz
Ritonavir
Indinavir sulfate
Nelfinavir
Nelfinavir Mesylate
U.S. FDA Resources
Further study details as provided by The HIV Netherlands Australia Thailand Research Collaboration:
Primary Outcome Measures:
- 1. To collect clinical and immunologic data of children treated with HAART 2. To collect clinical outcome data on children with HIV infection 3. To provide the best possible care to children with HIV infection [ Time Frame: every 3 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 200 |
| Study Start Date: | March 2003 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
Intervention Details:
Detailed Description:
-
Drug: Zidovudine, Stavudine, Didanosine, Lamivudine
Refer to the Thai guideline for HIV management 2007
Drug: Nevirapine, Efavirenz
Refer to the Thai guideline for HIV management 2007
Drug: LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir
Refer to the Thai guideline for HIV management 2007
This is a long term cohort study that was started in 2002. Currently, there are 120 children enrolled in the study and are receiving HIV care according to standard practice set by the Thai Ministry of Public Health. HIV-infected parents also receive care at the same clinic.
Eligibility| Ages Eligible for Study: | up to 20 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Children who are part of the ATC program at Chulalongkorn hospital and at HIV-NAT, The Thai Red Cross AIDS research center
- Children who fulfil criteria to start HAART according to the ATC program
- Children who are switched to second regimen or salvage therapy
- Children who are on any antiretroviral regimens, including post trial children from other HIV-NAT study (both at HIV-NAT and Khon Kaen University sites)
- Children with HIV infection who are not on antiretroviral therapy
- Caretakers understand the purpose of data and plasma samples collection, and have signed the consent form
Exclusion Criteria:
- Patients and caretakers may choose to stop HAART at anytime during the study. If they agree, we would continue to follow them in this study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00476606
Contacts
| Contact: Torsak Bunupuradah, MD | 662-652-3040 | Torsak.B@HIVNAT.org |
Locations
| Thailand | |
| HIV-NAT | Recruiting |
| Bangkok, Thailand, 10330 | |
| Contact: Torsak Bunupuradah, MD 662-652-3040 Torsak.B@HIVNAT.org | |
| Sub-Investigator: Torsak Bunupuradah, MD | |
| Sub-Investigator: Jintanat Ananworanich, MD | |
| Sub-Investigator: Thanyawee Puthanakit, MD | |
| Pediatric infectious diseases section, Chulalongkorn University | Recruiting |
| Bangkok, Thailand, 10330 | |
| Contact: Chitsanu Pancharoen, MD | |
| Khon Kaen University | Recruiting |
| Khon Kaen, Thailand, 40002 | |
| Contact: Pope Kosalaraksa, MD | |
| Sub-Investigator: Chulapan Engchanil, MD | |
| Sub-Investigator: Pagakrong Lumbiganon, MD | |
Sponsors and Collaborators
The HIV Netherlands Australia Thailand Research Collaboration
Khon Kaen University
Investigators
| Principal Investigator: | Kiat Ruxrungtham, MD, MSc | HIV-NAT, The Thai Red Cross AIDS Research Centre |
More Information
Additional Information:
Publications:
Bunupuradah T., Puthanakit T., Boonrak P., Butterworth O., Mengthaisong T., Intasan J., Ubolyam S., Kosalaraksa P., Engchanil C., Pancharoen C., Lumbiganond P., Phanuphak P., Ananworanich J., HIV-NAT Pediatric Study Team. Efficacy and safety of non nucleoside reverse transcriptase inhibitor (NNRTI) based highly active antiretroviral therapy (HAART) in Thai children with HIV, poster No. TUPEB128. Poster presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 22-25, 2007
| Responsible Party: | The HIV Netherlands Australia Thailand Research Collaboration |
| ClinicalTrials.gov Identifier: | NCT00476606 History of Changes |
| Other Study ID Numbers: | HIV-NAT 015 |
| Study First Received: | May 20, 2007 |
| Last Updated: | April 3, 2012 |
| Health Authority: | Thailand: Ministry of Public Health |
Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
|
HIV children HAART ARV Second line HAART |
Viral Load Combination drug Treatment Experienced Treatment Naive |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Didanosine Zidovudine Stavudine Nevirapine |
Lamivudine Efavirenz Indinavir Saquinavir Ritonavir Nelfinavir Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |
ClinicalTrials.gov processed this record on June 18, 2013